The latest clinical trial concluded that GnRHa, combined with tamoxifen or aromatase inhibitors, could improve disease free survival for hormone receptor positive (HR+) premenopausal high-risk breast cancer patients20. The gene discussed is NR4A1; the disease is breast cancer.